Search Results: (30 results)

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

This study aims to explore perceptions of patients and genetic counselors about long-term follow-up in cancer genetic counseling, including if and how patients would like additional follow-up with a genetic counselor beyond the pre- and post-test counseling session. If you wish to participate, email the student investigator to schedule a voluntary 30–60-minute Zoom interview. All information will be de-identified. There are no costs associated with participation. NOTE: This study is no longer enrolling. 

We would like to invite you to share your experiences to help improve the quality of life for Asian Americans diagnosed with metastatic cancer. NOTE: This study is no longer enrolling. 

Global Patients along with IQVIATM, a worldwide healthcare consulting firm, is currently conducting a research study, to better understand the experience of patients and/or caregivers of patients living with metastatic pancreatic cancer.

Researchers at MD Anderson Cancer Center are conducting telephone interviews with individuals who have received modified (also known as reclassified or amended) genetic test results in any cancer related gene. We are interested in learning about the experience of receiving a modified test result and decisions made. 

This is a study on how the practice of crowdfunding affects the experience of having cancer. With the support of the National Science Foundation (NSF award #2021152), the researcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. earcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. 

You are invited to participate in an anonymous online survey about your decision to do genetic testing and how you dealt with the uncertainty of the outcome. The online survey includes a newly developed Uncertainty Management Scale (UMS) based on our years of prior uncertainty research. Knowing more about how people manage uncertainty may be helpful to society. You will be compensated $10 for completing the survey. This study is no longer enrolling. 

This study is looking at how to improve access to genetic testing among Hispanic/Latino populations in the U.S. We are conducting interviews with people in the Hispanic/Latino community who have either received genetic testing for hereditary cancer risk, or who have a family history of hereditary cancer and/or cancer diagnosis. This study could help develop policy options to inform how to improve access to genetic testing. Email Amanda Gutierrez at [email protected] if you are interested in participating. NOTE: This study is no longer enrolling.

This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.

Researchers in the National University of Ireland, Galway are looking for people to take part in a survey on BRCA1/2 alteration carriers and health behaviours. The once-off survey asks questions about how you cope and what you think about health behaviours. Note: This study is closed to enrollment.

In less than 5 minutes, learn which medical records are important to keep after a cancer diagnosis, why they are important to save, and ideas of how to keep them for you and your family.  The study has been IRB-approved by UC Irvine and is available in English and Spanish!  Note: This study is now closed to enrollment.

This study investigates why women share aspects of their previvorship identity on social media platforms. We are interviewing women above 18 years old, who carry known pathogenic variants in BRCA1 or BRCA2, and share their previvor journey on social media platforms like Instagram, Facebook, Twitter, and TikTok at least once every other week. We are conducting anonymous interviews over Zoom with women who qualify. If you are interested, contact Mariah Wellman at [email protected]. NOTE: This study is no longer enrolling people. 

This study looks at why women at an increased risk of developing breast cancer are interested or uninterested in participating in breast cancer prevention clinical trials. The study consists of a 10-15 minute (max) anonymous questionnaire that asks hypothetical questions about participating in clinical trials with various study designs. This study’s findings may be used to better inform how to best design clinical trials aimed at the prevention of a breast cancer in the future. NOTE: This study is no longer enrolling.

This anonymous survey is being conducted by researchers at the National Human Genome Research Institute of the National Institutes of Health, in collaboration with Facing Our Risk of Cancer Empowered (FORCE). The goal of this survey is to help researchers understand the caregiving experiences of families affected by hereditary cancer. By sharing your experience with us, you can help us develop more resources to improve the experience of future family caregivers.  NOTE: THIS STUDY IS NO LONGER ENROLLING.

This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence. NOTE: This study is no longer enrolling. 

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer.  The research hopes to identify areas for improvement in supporting the lives of people who care for patients living with ovarian cancer. By taking part in the survey your views, alongside those of other caregivers of women living with ovarian cancer will be heard. This will help generate the scientific evidence required to ensure healthcare professionals and other healthcare supporting bodies have a deep understanding about what it is like to live with advanced ovarian cancer and can help provide them with the tools to support patients, caregivers, and their families. NOTE: This survey is closed to enrollment.

This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized). NOTE: This study is no longer enrolling patients. 

This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes. NOTE: This study is no longer enrolling patients. 

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of an immunotherapy plus targeted therapy and chemotherapy works compared with chemotherapy alone.  NOTE: This study is no longer enrolling people. 

The TALAPRO-2 study is assessing whether the study drug is safe and effective when given in combination with enzalutamide as a treatment option for men with metastatic castration-resistant prostate cancer and DDR deficiency. NOTE: This study is no longer enrolling patients. 

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer and preference for different ways of taking medication.  The research hopes to identify areas for improvement in supporting the lives of patients living with ovarian cancer and the people that care for them after 1st surgery and chemotherapy.  NOTE: This survey is closed to enrollment.

We are looking to interview Black women who have received a positive result in a cancer-associated genetic test. We want to hear your story. This research will look at Black women's experiences with cancer genetic testing. If you decide to take part in the study, you would participate in an approximately hour-long phone interview. Participants will be compensated for their time with a $20 gift card. Contact Malika Sud at [email protected] for more information or to participate. NOTE: This study is now closed. 

The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

We are investigating the relation of adversity, pain, and fear of cancer recurrence among adult cancer survivors. Participation involves completing a 30-minute computerized survey online from your home computer. No compensation is being offered for participation in this research study.

Researchers are conducting a study to test how well education materials increase use knowledge about hereditary cancer risk. Participants will watch 90 minutes of educational videos and complete 2 short surveys. In all, this will take approximately 3 hours to complete over a two-week period. Everything will be completed over the phone or online. Compensation will be provided for participation. NOTE: This study is no longer enrolling participants. 

This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.

• Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• Immunotherapy such as dostarlimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. 

AMPLIFY is a nation-wide, web-based diet and exercise study recruiting overweight survivors of early stage breast, prostate, ovarian, renal, colorectal and endometrial cancer and multiple myeloma. This study is enrolling qualified cancer survivors age 50 and older who are interested in becoming more active, eating better and losing weight.

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors).